Properties
What is it?
International Nonproprietary Name - methylglucamine acridonacetate Dosage form: 12.5% solution for injection Composition: 1 ml of solution contains 0.125 g of acridoneacetic acid (main active component) and 0.0963 g of N-methylglucamine (salt-forming and stabilizing additive), the rest is water for injection. Description: Transparent, yellow liquid Pharmacotherapeutic group: Immunostimulant. ATC code: [L03AA]. Indications: Cycloferon is used for adults for: • HIV infection (stages 2A-3B); • Neuroinfections: serous meningitis and encephalitis, tick-borne borreliosis (Lyme disease); • Viral hepatitis A, B, C, D; • Herpes and cytomegalovirus infection; • Secondary immunodeficiencies associated with acute, chronic bacterial and fungal infections; • Chlamydial infections; • Rheumatic and systemic connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus); • In complex therapy of degenerative-dystrophic joint diseases: deforming osteoarthritis, etc. For children over 4 years of age for: • Viral hepatitis A, B, C, D, GP; • Herpes infection; • In complex treatment of HIV infection (stages 2A-3B). Method of administration and dosage: 1. In adults: Cycloferon is administered intramuscularly or intravenously once a day according to the basic scheme: on days 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29, depending on the disease. For viral hepatitis, the drug is used in a single dose of 0.25-0.5 g. The course of treatment consists of 10 injections according to the basic scheme. The total dose is 2.5-5.0 g. The course is repeated after 10-14 days. For herpes and cytomegalovirus infection - 10 injections of 0.25 g according to the basic scheme. The total dose is 2.5 g. Treatment is most effective at the beginning of the exacerbation of the disease. In case of neuroinfections, the drug is administered according to the basic scheme. The course of treatment consists of 12 injections of 0.25-0.5 g, along with etiothropic treatment. The total dose is 3-6 g. The course is repeated as needed. For chlamydial infection - a dose of 0.25 g. The course of treatment consists of 10 injections. The total dose is 2.5 g. The course is repeated after 10-14 days. It is recommended to take Cycloferon with antibiotics. For HIV infection (stages 2A-3B) - a single dose of 0.5 g. The course of treatment consists of 10 intramuscular injections according to the basic scheme. The total dose is 5 g. Subsequently, a maintenance course is carried out: once every two and a half months. The course is repeated one month after the previous course of treatment. For immunodeficiency states, the course of treatment consists of 10 intramuscular injections according to the basic scheme with a single dose of 0.25 g. The total dose is 2.5 g. The course is repeated after 6-12 months. For rheumatic and systemic connective tissue diseases - 4 courses of 5 injections according to the basic scheme, 0.25 g, with 10-14 day intervals. The course is repeated according to the doctor's recommendation. For degenerative-dystrophic joint diseases - 2 courses of 5 injections of 0.25 g, with 10-14 day intervals, according to the basic scheme. The course is repeated according to the doctor's recommendation. 2. In children: In pediatric practice, Cycloferon is administered intramuscularly or intravenously once a day. The daily therapeutic dose is 6-10 mg/kg of body weight. For acute viral hepatitis A, B, C, D, GP and mixed forms, the drug is administered on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28. In case of prolonged course of infection, the course is repeated after 10-14 days. For chronic viral hepatitis B, C, D, GP, the drug is administered on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 18 of the treatment course, and then according to a maintenance scheme once every three days for three months, if the replicative and cytolytic activity of the pathological process is maintained. For HIV infection, the drug is administered on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 18 of the treatment course, and then according to a maintenance scheme once every five days for three months, if the replicative activity of the pathological process is maintained.